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Abstract
The general area of the research is Health Informatics. The research focuses on creating
an innovative and novel solution to manage and analyze clinical trials data. It constructs a
Graphical Database Architecture (GDA) for Clinical Trials (CT) using New Technology for Java
(Neo4j) as a robust, a scalable and a high-performance database.
The purpose of the research project is to develop concepts and techniques based on
architecture to accelerate the processing time of clinical data navigation at lower cost. The
research design uses a positivist approach to empirical research.
The research is significant because it proposes a new approach of clinical trials through
graph theory and designs a responsive structure of clinical data that can be deployed across all
the health informatics landscape. It uniquely contributes to scholarly literature of the phenomena
of Not only SQL (NoSQL) graph databases, mainly Neo4j in CT, for future research of clinical
informatics. A prototype is created and examined to validate the concepts, taking advantage of
Neo4j’s high availability, scalability, and powerful graph query language (Cypher).
This research study finds that integration of search methodologies and information
retrieval with the graphical database provides a solid starting point to manage, query, and
analyze the clinical trials data, furthermore the design and the development of a prototype
demonstrate the conceptual model of this study. Likewise the proposed clinical trials ontology
(CTO) incorporates all data elements of a standard clinical study which facilitate a heuristic
overview of treatments, interventions, and outcome results of these studies.
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CHAPTER 1
INTRODUCTION
The Modernization of the medical and healthcare industries continues to experience
numerous challenges despite its major successes in the past two decades. Development of
concepts and techniques to help solve the healthcare problems is the focal point of such
challenges. The results of these problems varies from a problem to another. The causes for these
challenges include several factors. The first factor is the absence of open software systems’
integrity. The second factor is an inefficient medical and healthcare information retrieval
processes. The third factor is redundant and inaccurate data. The fourth factor is IT inability to
align with the business strategy. Finally, poor quality of information results in lack of
information that analysts require to plan strategy for the medical and healthcare industries.
This research encompasses medical and healthcare organizations; that include its
domains, its employed technology, product scope, customer orientation, and markets (Creswell,
2003). This study focuses on an innovative solution to aggregate, manage, mine, and analyze
clinical trials data and improve compliance with the original Health Information Technology
Standards (Bowen, 2011). The research develops a Graphical Database Architecture (GDA) for
Clinical Trials (CT). It captures the challenges of clinical trials data to develop concepts and
techniques based on the architecture to help solve the problems of data management. Our longterm goal is to define and implement an innovative intelligent open source software system to
decrease the problems associate with clinical trials data in healthcare using cultural algorithm
such as swarm algorithm. Figure 1 describes paradigm of the graphical database architecture that
consist of three layers, user layer which where the user inter a search term or a cypher query, the
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graphical database clinical trial layer, and the data sources layer. This layer retrieve the data from
the clinical trials site or the database management component.

Figure 1. The Architecture of Graphical Database for Clinical Trails
This study is a new attempt to apply GDA principles by providing dynamic services that
have concrete meaning on the medical and healthcare industries level to reduce costs, resources,
time, overhead, and minimize health risks. The implementation of GDA has acceptable benefits
such as agility, integrity, and a long-term strategy. This strategy increases flexibility of the
healthcare IT infrastructure (El-Bathy & Gloster & Azar, 2012). New medical and healthcare
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requirements will be developed in the short term via the reusability of existing business logic and
data models (Watson, 2006).
The development of an automated Graphical Database Architecture for Clinical Trials
system is regarded as a major and a significant component for clinical trials data. Researchers
have often studied general technical types of information systems which cannot entirely solve the
problems of Medical and Healthcare information. Therefore, the reality is that the industries’
organizations still face severe obstacles mainly in managing clinical trials information that have
adapted over time based on doctors' requests. Our system will allow medical personnel to query
a database to determine if similar clinical trials have previously been conducted
The required elements for choosing the area of the study for this research have been
established based on extraordinary experience in Information Technology, Healthcare
organizations, and an Academic Degree. The problem has emerged as management of clinical
trials data that healthcare professionals encounter. The reasons for such problem are inefficient
Medical and Healthcare information retrieval processes due to numerous grounds. These
primarily include huge redundant data, data inaccuracy, IT inability to align with the business
strategy, and the absence of software systems’ integrity (Watson, 2006).
Thus, efficiency, performance, and quality are essential to eliminate not only the effects
of the problem but also its causes. Hence, the long-term goal is to define and implement an
innovative Graphical Database Architecture (GDA) for Clinical Trials (CT) to improve the
accuracy of Clinical Trials data through accelerated information retrieval. However, determining
the requirements for accomplishing the long-term goal is the main part for successfully achieving
the specified objectives. The study for this research establishes a prototype model that supports
the alignment between IT goals and Medical and Healthcare organizations strategy. The
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prototype model defines a target technology environment that supports the organization strategic
plan. It allows an organization to meet its strategic, tactical, and operational needs, and updates
IT processes. Not only is the performance of an organization improved by applying the
methodology of strategic alignment, but also the organization’s effectiveness (Gutierrez &
Serrano, 2008). A successful IT strategic plan is based on four main priorities. These are ITbusiness alignment escalation, IT governance enhancement, IT significance improvement, and IT
investments grade. The IT strategic plan should follow a timetable via a roadmap and it is
exposed to alteration based on the business process changes (Cullen & Cecere & Symons &
Cameron & Cardin & Orlov & Belanger, 2007).
The development of IT strategic plan consists of five phases. These phases include the
purpose of the plan, the business requirement, and the business requirements’ validation. The
phases also include the procedures needed for eliminating the gaps between the state of “to be”
and the IT processes state, and the plan approval (Cullen & Cecere & Symons & Cameron &
Cardin & Orlov & Belanger, 2007).
In this research, the concept of big Data is poised to deliver revenues efficiently for
enterprises such that innovation of healthcare information technology (IT) will change fast in
few decades (Chambers; Dhiraj, & Minelli, 2013). According to International Data Corporation
in 2012, Figure 2 depicts the growth of data from 2005 to 2017.
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Figure 2. Data Size explosion
Figure 3 shows a timeline of recent technology developments (Chambers; Dhiraj, &
Minelli, 2013). Back in the 1980s enterprise resource planning systems (ERP) (i.e. SAP) were
the central component of any corporation information system ecosystem, then more sophisticated
and specialized systems emerged like customer relationship management (CRM) that manage a
company’s collaborations with customers, the new millennium was associated with the dot com
boom or internet boom, and now the narrative is to consider methods and concepts to manage the
data explosion using machine learning systems, data mining, and big data solutions.

Figure 3. Timeline of Recent Technology Developments
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In clinical trials, data accessibility is required to be provided at user-level based on user’s
queries and queries' results analysis. The users are insurance companies, pharmaceutical
companies, professional medical staff, doctors, schools, and research centers. Further the clinical
trials data provide a valuable source of information that can be useful for all medical
professionals to gain insights on the conducted interventional and observational clinical studies
One of the technologies used to aggregate, manage, mine, and analyze big data is nonrelational databases because the database does not store data in traditional tables and link tables
to each other through relationships (Kumar Singh, 2011). In the same direction NOSQL an
acronym for Not Only Structured Query Language intended for managing data in non-relational
databases. But still have the ability to create, insert, query, update, and delete data in a schemaless landscape (Vaish, 2013).
1.1 Problem Statement and Research Questions
The problem of this research is identified as unnecessary treatments and testing for
diseases. This problem is a result of unproductive medical and healthcare information retrieval
processes. This research addresses the need for software systems that allow medical and
healthcare organizations to meet its strategic, tactical and operational goals faster at lower cost
(El-Bathy & Gloster & Azar, 2012).
One specific research question which arises is: How can the integration of search
methodologies, information retrieval, and graphical database be used to determine the best
treatment for a certain disease using clinical trials data?
Querying a database requires that the user has developed a deep knowledge of database
concepts. This requirement may include the following: concepts of table fields and tuples,
primary and foreign keys, entities and relationships (Guimarães da Silva, 2014). It also requires
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that the user masters a database query language such as SQL. Additionally, querying requires
that the user knows what kind of data is stored in the database, in order to define what to query.
Given these restrictions, the user's task of querying a database requires a cognitive overload
which may not be overlooked, in part because typical users do not have such theoretical
knowledge and do not know the internal organization of the database to be queried (Guimarães
da Silva, 2014).
When analyzing a query's results provided by a Relational Database Management System
(RDBMS), it is difficult to get a data overview and to detect patterns, and trends in the data.
Graphical and interactive representations of data, as proposed by the Information Visualization
area (Card et al., 1999) are appropriate for this kind of analysis. They provide distinct levels of
data overview, details on demand, and interactive capabilities of data reorganization and
filtering, among other useful resources.
Interactive filtering techniques such as dynamic queries provide user controls for
selecting relevant data and for querying details, providing fast answers without the need to learn
command-line querying syntax. When applied together, filtering and other techniques enhance
users' formulation of an internal model about the data analysis (Shneiderman, 1994).
This research study proposes the following steps to create a Graphical Database
Architecture (GDA) for Clinical Trials data for data mining, data management, data
visualization, and data accessibility capabilities:
1. Collect clinical trials data in Extensible Markup Language (XML) format
2. Wrangling, cleaning, and preparing data (Convert xml to Neo4j format)
3. Create a graphical database model in Neo4j
4. Generate nodes and edges for the Neo4j graphical database.
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5. Load the converted clinical trials data into the created Neo4j graphical database by
executing Cypher statements
1.2 Purpose of Research
The purpose of this research is to use a new type of database, a database that uses graph
structures with nodes, edges and properties, to represent and store information. The GDA tests
the efficiency and effectiveness compared to the relational database management systems. This
requires building and designing a graphical database to extract and process clinical trial data to
be analyzed, published, and shared. A key feature of graph databases is they offer a unique
vantage point of data, where the solution to a problem is seen as a conceptually defined
traversals through its vertices and edges.
Clinical trials are used to evaluate what treatment works best against a certain disease
based on data acquisition, management, retrieval, and analysis. Clinical trials have to be planned,
designed, and tested.
This research study proposes a solution that provides data management capabilities, data
collection, data representation, data navigation, and mining using the query language of graph
databases specifically Neo4J’s language Cypher. The study uses the solution as a database (DB)
management tool and a learning management system.
Though there are several excellent general reviews of NoSQL databases and technologies
each to some extent reflects the authors’ personal research interests and expertise. Due to the
pace of development and breadth of research, a truly comprehensive review is beyond the scope
of this thesis.
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1.3 Significance of the Research
A study of analyzing clinical trials data to identify more indications and discover adverse
effects. The study to analyze, near real-time collections of adverse case reports enables
identifying events that were hinted at in the clinical trials but that did not have sufficient
statistical significance.
So this research study proposes a new concept. It defines a new mechanism for data
management. By using graph databases of NoSQL, faster traversing is accomplished. Also,
joining or merging relationships is very fast and efficient. The relationship between nodes is not
calculated at query time but persists as a relationship. Traversing persisted relationships is faster
than calculating them for every query.
Semi-structured data models are oriented to model semi-structured data (Buneman &
Abiteboul, 1997). They deal with data whose structure is irregular, implicit, and partial, and with
schema contained in the data. One of these models is OEM (Object Exchange Model)
(Papakonstantinou, Garcia-Molina & Widom, 1995). It aims to express data in a standard way to
solve the information exchange problem. This model is based on objects that have unique
identifiers, and property value that can be simple types or references to objects. Another data
model is the XML data model (Bray, Paoli, Sperberg-McQueen, Maler, & Yergeau, 2006). XML
has an ordered-tree like structure and the information about data in XML is part of the data set.
Semi-structured documents, such as XML, can be effectively modeled using a rooted ordered
labeled tree or graph. A graph consists of a set of nodes (or vertices) that are connected by edges.
Each edge has two nodes associated with it. A path is defined as a finite sequence of
edges that connect nodes. A rooted tree has its top-most node defined as the root that has no
incoming edges and there is a single unique path between any two nodes. A node u is said to be a
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parent of node v, if there is a directed edge from u to v. Node v is then said to be a child of node
u. Nodes with the same parent are called siblings. The ancestors of a node u are the nodes on the
path between the root and u, excluding u itself. The descendants of a node v can then be defined
as those nodes that have v as their ancestor.
1.4 Contribution to Knowledge
This research study is a new hypothetical concept defining the requirements for a
graphical database model for clinical trials data. It integrates data mining capabilities,
visualization representation, and better performance to help many stakeholders who are involved
in one or another in the clinical trials field like insurance companies, pharmaceutical companies,
professional medical staff, doctors, schools, and research center.
This study adds to the field of health informatics by applying an innovative model and a
new way of handling semi-structured data. The new concept try to introduce a dynamic graphical
database model that provides efficiency, high availability, handling a huge number of nodes (32
billion), edges (32 billion), and up to 64 billion properties. That will allow all stakeholders
involved or interested in clinical trials data to utilize it for better data management and faster
processing time. Although giant steps have been made in recent years in the field of health
informatics, there remains an open question as to improve, find new way of to answer research
questions.
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CHAPTER 2
LITERATURE REVIEW
This review is intended to summarize current knowledge about Medical and Healthcare
organizations. It is a crucial mechanism for the development of a new theory to accelerate
processing time, and provide a new direction for future research and management of the
alignment of IT goals with Medical and Healthcare organizations strategy.
In the literature analysis, alternates are used to differentiate between the characteristics of
the information that had been saved in files on a computer as a soft copy and the information that
had been saved in less thoroughly reviewed outlet.
This chapter identifies more focused literature requirements for the literature survey
phase of the research. More specific topics give a solid background and knowledge to develop a
model and methodology to solve the research problems.
This research study builds the prototype model. Building stage is the phase of the
requirements, design, specifying software tools, and designing the interfaces. Prototyping stage
is the phase of coding and testing.
The purpose of this study is to verify that the model works. The model provides
prototyping stage developer with outlines to follow. There are three approaches. The first is top
down. That is, the research starts from the top component and ends with the bottom component.
The second is bottom up; the research starts from the bottom component and ends with the top
component. The third is hybrid; the research starts from the middle of the model and ends with
both the top and bottom components.
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2.1 Health Informatics
Health informatics is a developing field that is becoming progressively important to the
quality and effective distribution of healthcare. Now any modern health organization can’t
function efficiently without an electronic database storing, processing, and communicating
patient-related data. With the increasing complexity of chronic illness and the number of
medications prescribed in an elderly population, information technologies and decision support
tools can be used to help to prevent medication errors, improve the analyzing capabilities of the
health and medical data (Lui, 2010).
As an academic discipline evolves, one naturally asks what makes it different from
existing fields and how do the practitioners of the discipline stand out from current workers. This
chapter of the thesis presents the link between health informatics (HI) especially Clinical trials
data and the graph databases, the development of health informatics (HI) as a discipline and how
this relates to the people who work in it will be investigated.
Health informatics (HI) is the scientific discipline concerned with the creation, storage,
processing, transmission, and use of health-related data, information and knowledge (Shortliffe
& Cimino, 2006, p. 24).
It is a broad field and its workers have a wide range of responsibilities and tasks. Part of
the reason for the breadth is the natural evolution of health informatics (HI) as a discipline. The
origin of the formal discipline was strongly influenced by the development of the electronic
computer. Indeed, the term informatics came from European developments in computer science.
Informatics was probably first created by the father of German computer science, Karl
Steinbuch, in his 1957 paper, “Informatik: automatische informationsverbeitung”, which
translates to “Informatics: automatic information processing” (Widrow, Hartenstein, & Hecht-
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Nielsen, 2005). The french computer science pioneer, Philippe Dreyfus, used the term in
establishing the Société d’Informatique Appliqueé in 1962 (Fourman, 2002, p. 1)
Informatics became more to do with information rather than simply computers. However,
readers should be wary; there are many who consider informatics a field of computer science, or
indeed as a synonym (Buerck & Feig, 2006; Kane, Brewer, Goldman, & Moidu, 2006; Smith &
Buerck, 2007).
Whether information exists in print or in bits and bytes, health knowledge cannot be used
if it cannot be accessed. Psychology, and in particular, cognitive science, indicates how health
practitioners think and work and how computer systems might best be designed to support them
e.g. understanding the cognitive workings of health workers that lead to the failure of a neonatal
intensive care decision-support system (Alberdi, et al., 2000).
Health informatics (HI) supports all processes including administration, governance,
clinical care and research. Since the informational problems encountered in certain areas can
differ in content, subareas of health also have their own informatics knowledge; one can
recognize subfields such as medical informatics, nursing informatics, public health informatics,
patient (consumer) informatics and pharmacy informatics. As for computing, it has been said that
the computer scientist is a tool smith, and his success is determined by whether people use his
tools (Brooks, 1996).
Healthcare tracks a specific biomedical scientific paradigm, where there is an obligation
on understanding the scientific principles behind healthcare activities. This differs from the
engineering perspective to which IT professionals are accustomed (Tichy, 1998; Zannier,
Melnik, & Maurer, 2006). Drug therapy is a good example; health professionals require scientific
proof that a drug is beneficial, often in the form of controlled experiments (clinical trials).

15
Clinical informaticians: This is a role that extends the idea of the ad hoc health IT worker
from early history; these people were health workers who picked up IT as it became incorporated
into health organizations. Today, a formal place is recognized for those who hold dual roles as
clinicians (doctors, nurses, etc.) and health informaticians. Health Informatics is, and should be,
driven by health informational problems. The best exposure to such informational problems is
active clinical practice. These people are seen by general clinicians as understanding the nature
of health service delivery and as a referral point for informational problems. Indeed, clinical
informaticians can make up part of a clinical team. Just as the ad hoc pioneers became beacons
for health informatics (HI), they too become a visible resource for others and are the modern day
champions. Recently, the American Medical Informatics Association began work on formalizing
clinical informatics as a specialist area for physicians; these individuals combine their knowledge
of patient care and informatics methods and tools to assess the knowledge needs of health
workers and patients, and to develop and evaluate clinical computer systems (Safran et al.,
2009).
Health Informatics is the scientific discipline concerned with how best to use data,
information and knowledge in medicine to improve patient care. Information science principles
and computer and communications technology are the tools that Health Informatics professionals
use. The field is still evolving but one can demonstrate that professionalism exists. There is a
body of scientific theory, set of skills, knowledge and competencies, and professional attitudes
shared by practitioners, despite a range of informatics roles.
The need for Health Informatics specialists is clear. The domain expert-IT paradigm is
insufficient for non-trivial health computing. The Health Informatics professional brings her
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knowledge of health and a wider kit of tools and understanding to apply to informational
problems.
The Health Informatics professional is likely to become increasingly important to
healthcare organizations, clinicians and patients as the cost and complexity of healthcare increase
and as technologies advance and become more useful. Education will continue to play an
important role in the qualification of Health Informatics professionals, despite the various
standards and curricula present today. Similarly, certification/accreditation and regulatory bodies
will become increasingly relevant; a number of professional associations currently exist and
matters of jurisdiction will have to be addressed.
2.2 Clinical Trials
Although clinical trials are a substantial and rapidly growing international business, they
are not well understood by the general public. They are often seen as obscure and are sometimes
surrounded by controversy about the ethical aspects that touch the nature of the early side affects.
Clinical trials are a systematic and rigorous procedure to distinguish successful therapies
and medicines from unsuccessful ones. Gradually, more structured experimentation began to
take place. Experiments of the British naval doctor James Lind in the mid-eighteenth century
were designed to discover the causes of scurvy, a disease that had decimated British naval crews.
The experiments relied on comparative groups of men, giving one group vinegar and the
other group citrus fruits to treat scurvy. As a result of these experiments, which demonstrated the
efficacy of oranges and lemons against scurvy, the Royal Navy began supplying citrus fruits to
its ships in 1795. However, it took more than a hundred years from those early experiments for
the modern system of drug testing to be born.
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While in the United States, not until 1938 did the U.S. Food Drug and Cosmetic Act
subject new drugs to premarket safety evaluation and require Food and Drug Administration
(FDA) regulators to review both preclinical and clinical test results. However, even this law did
not precisely specify the kinds of tests required for approval, so it gave regulators only limited
powers for negotiation with the pharmaceutical industry. Public health disasters caused by poorly
tested drugs, such as thalidomide, showed that the system was not adequate to the task. The
thalidomide disaster and other, similar ones ultimately prompted the passing of the 1962 Drug
Amendments. Those laws explicitly stated that new drug approvals would rely on substantial
scientific evidence of a drug’s safety and efficacy. Therefore, the FDA was obliged to base its
approvals on “adequate and well-controlled studies.” The modern clinical trial, based on
statistically controlled, evidence-based results, was born and eventually became the requirement
for new drug approvals by the FDA. The FDA approval procedure is regarded today as a world
standard of the drug industry.
Preclinical studies involve two types of experiments: test tube ones, known as “in vitro,”
and also experiments carried out with animals or cell cultures, known as “in vivo.” The
experiments apply different doses of the drug under study to develop acute toxicity and toxicity
ranges and to establish a pharmacological profile of the drug. The tests’ results inform the
decisions related to granting the drug candidate with an investigational new drug (IND) status
and open the way for further testing of the drug candidate under the actual clinical trials regime.
Clinical trial (also called an interventional study), the participants receive specific
interventions according to the research plan or protocol created by the investigators. These
interventions may be medical drugs or medical devices; medical procedures; or applying changes
to participants' behavior. When a new product or approach is being studied, it is not usually
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known whether it will be helpful, harmful, or no different than available alternatives so the
investigators work to determine the safety and efficiency of the proposed intervention by
measuring specific outcomes on the participants.
Generally clinical trials used in drug development are described or divided by phase.
These phases (will be discussed later) are defined by the Food and Drug Administration (FDA).
A principal investigator usually led the clinical trial, a research team consists of doctors,
physicians, nurses, and health care professionals’ works under the supervision of the
investigator. These trials take place in different locations hospitals, research centers, medical
schools, and a community of health professionals. ("Learn About Clinical Studies." Home. N.p.,
n.d. Web. August. 2012).
Clinical trials are planned to add to medical knowledge related to the treatment,
diagnosis, and prevention of diseases. To be precise:


Evaluating interventions for treating a disease, syndrome, or condition



Finding ways to prevent the initial development or recurrence of a disease or
condition.



Examining methods for identifying a condition or risk factors for that condition



Exploring ways to measure and improve the comfort and quality of life of people with
a chronic illness.

Figure 4 illustrates that actual clinical trials of a new drug typically proceed in four
phases. Phase I trials constitute the first stage of testing in human subjects. Usually, a small
group of 20–100 healthy volunteers are selected. Phase I includes trials designed to assess the
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safety profile and initial tolerability, pharmacokinetics, and pharmacodynamics of a drug
candidate.
Phase II is performed on larger groups (100–300) of patients who have the disease the
drug aims to treat or prevent, to determine preliminary effectiveness. This outcome is designated
as confidence in mechanism (COM). Safety assessments that started in phase I are continued, but
in a larger group of volunteers and patients to assess common short-term side effects and risks of
the drug candidate. These safety tests should result in reaching a milestone called confidence in
safety (CIS). Phase II studies are sometimes divided into phase IIA (related to frequency of
dosing) and phase IIB (efficacy at prescribed dosage).
Phase III trials expand upon the preliminary data for effectiveness and monitor longerterm safety to determine the overall benefit–risk profile in larger groups of patients. The results
form the basis that informs the labeling information, which determines marketing elements of the
new drug. Phase III is costly and usually constitutes the “pivotal trials” regulators weigh strongly
in their approval or disapproval decision
Phase IV in some scenarios, some clinical trial studies may need to be conducted as well
as the larger ‘pivotal’ studies. However, if these studies are small may not be necessary before
submitting for licensing approval but are conducted after approval and are called phase IV
(O'Neill & Hopkins, 2011)
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Exploratory study involving very limited
human exposure to the drug, with no
therapeutic or diagnostic goals

Phase 0

conducted with healthy volunteers and that
emphasize safety. The goal is to find out what
the drug's most frequent and serious adverse
events are and, often, how the drug is
metabolized and excreted.

Phase 1

Studies that gather preliminary data on
effectiveness (whether the drug works in people
who have a certain disease or condition). .
Safety continues to be evaluated, and shortterm adverse events are studied.

Phase 2

Studies that gather more information about
safety and effectiveness by studying different
populations and different dosages and by using
the drug in combination with other drugs .

Phase 3

Studies occurring after FDA has approved a drug
for marketing. . These studies gather additional
information about a drug's safety, efficacy, or
optimal use.

Phase 4

https://clinicaltrials.gov/ct2/help/glossary/phase

Figure 4. Clinical Trials Phases
2.3 NOSQL Databases
For over decades, relational databases have been used to store structured data. The data is
sub-divided into groups, referred to as tables (Vaish, 2013). The tables store well-defined units
of data in terms of type, size, and other constraints. Each unit of data is known as a column while
each unit of the group is known as a row. The columns may have relationships defined across
themselves, for example parent-child, and hence the name relational databases. And because
consistency is one of the critical factors, scaling horizontally is a challenging task.
2.3.1 NOSQL. With the growth of big web applications, research has poured into
handling data at scale. One of the outputs of these studies is non-relational database, in general
referred to as NoSQL database. One of the main problems that a NoSQL database solves is scale,
among others (Vaish, 2013).
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Clearly NoSQL databases don’t use SQL. But most of them do have query languages,
and it makes sense for them to be similar to SQL in order to make them easier to learn.
An important characteristic of these databases is that they are generally open-source projects.
Although the term NoSQL is frequently applied to closed-source systems, there’s a notion that
NoSQL is an open-source phenomenon (Fowler & Sadalage, 2012).
Most NoSQL databases are driven by the need to run on clusters, and this is certainly true
of those that were talked about during the initial meetings about NoSQL. This has an effect on
their data model as well as their approach to consistency. Relational databases use ACID
transactions to handle consistency across the whole database. This inherently clashes with a
cluster environment, so NoSQL databases offer a range of options for consistency and
distribution.
NoSQL databases operate without a schema, allowing freely adding fields to database
records without having to define any changes in structure. This is particularly useful when
dealing with non-uniform data and custom fields which force relational databases to use names
like customField6 or custom field tables that are awkward to process and understand.
March 2009 InfoWorld article entitled NoSQL Databases Break All the Old
Rules (Wayner, 2009) described a set of data storage and access technologies that had been
developed by Web giants like Google and Amazon and were being adversely impacted by the
open-source software community. Since then, the term NoSQL database has become something
of a battle-cry, a marketing meme, and a label attached to more than a hundred products, some of
which pre-date the label by many years (Edlich, 2012). Anything that defines itself by what it’s
not is literally unbounded, so it’s unsurprising that even the meaning of the term—No SQL or
Not only SQL—is also morphing.
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2.3.2 Relational Database Management Systems (RDBMS). A relational database
management system (RDBMS) is a software application tool. It provides the capabilities of
controlling, managing, and administrating an organization's data storage. It is the tool that
utilized to create a relational database using Structured Query Language (SQL). Atomicity,
Consistency, Isolation, Durability (ACID) is a concept that ensures the reliability of database
transactions processing. A transaction is a database operation (Brewer, 2000).


Atomicity: Everything in a transaction succeeds lest it is rolled back. SQL carries this
principle internally. An INSERT statement inserts an entire set of rows into a table;
a DELETE statement deletes an entire set of rows from a table; an UPDATE statement
deletes and inserts entire sets (Celko, 2013).



Consistency: A transaction cannot leave the database in an inconsistent state. In SQL this
means that all constraints are TRUE at the end of a transaction. This can be because the
new state of the system is valid, or because the system was rolled back to its initial
consistent state.



Isolation: One transaction cannot interfere with another.



Durability: A completed transaction persists, even after applications restart.

Beyond ACID, there are three core systemic requirements that exist in a special
relationship when it comes to designing and deploying applications in a distributed environment
(Brewer, 2000). The three requirements are: Consistency, Availability and Partition Tolerance or
CAP.


Consistency: A service that is consistent operates fully or not at all.



Availability: means just that the service is available to operate fully or not at all.
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Partition Tolerance: means that a given system continues to operate even with data loss
or system failure.

2.3.3 Key Advantages of NoSQL. The key advantages of NoSQL include:


Schema-less: Almost all NoSQL implementations offer schema-less data representation.



Less time



Speed



Scalability
2.3.4 RDBMS VS. NoSQL. Many aspects compared between the traditional RDBMS

solutions and NoSQL databases. Table 1 illustrates the main difference between the traditional
relational databases management systems (RDBMS) and NoSQL in terms of flexibility, query
complexity, and scalability. These features are qualitative in nature the draws the outline of each
type key characteristics.
Table 1.
Comparison between RDBMS and NoSQL
RDBMS

NoSQL

Identify actors: The first step in the

Schema flexibility: store data as columns as

traditional approach is to identify various

opposed to rows in RDBMS. This allows

actors in the application. The actors can be

flexibility of adding one or more columns as

internal or external to the application.

required, on the fly. Similarly, document
stores that allow storing semi-structured data
are also good options.
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Table 1.
Cont.
Define models: Once the actors are identified, Complex queries: NoSQL databases do not
the next step is to create models. Typically,

have support for relationships or foreign keys.

there is many-to-one mapping between actors

There are no complex queries. There are

and models, that is, one model may represent

no JOIN statements.

multiple actors.

Define entities: Once the models and the

Data update: Data update and

object-relationships—by way of inheritance

synchronization across physical instances are

and encapsulation—are defined, the next step

difficult engineering problems to solve.

is to define the database entities
Define relationships: One of more important

Scalability: NoSQL solutions provide greater

steps is to be able to well define the

scalability for obvious reasons. A lot of

relationship between the entities.

complexity that is required for transaction
oriented RDBMS does not exist in ACID
non-compliant NoSQL databases.

2.3.5 NOSQL Categories. In this section, the main NoSQL databases and their
application are identified. Worth noting that Key-values databases and Document databases are
more mature than the Graph databases in terms of years of development, commercial brands, the
variety of vendors, and years of accumulated knowledge.
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2.3.5.1 Key-Value Stores. Key-value stores are the simplest NoSQL data stores to use
from an API perspective. The client can either get the value for the key, put a value for a key, or
delete a key from the data store. It allows the storage of a value against a key. Similar to a
document store, there is no need for a schema to be enforced on the value. However, there are
few constraints that are enforced by a key-value store (Vaish, 2013). Figure 5 shows example of
a set value against a key.

Figure 5. Example of Set a value against a key
Advantages of Key-value Stores:


Consistency



Transactions



Optimized Querying

Key-value stores Databases are good for:


Session information



User profiles



Shopping Cart

2.3.5.2 Document Databases. The database stores and retrieves documents, which can be
XML, JSON, BSON, etc. These documents are self-describing, hierarchical tree data structures
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which can consist of maps, collections, and scalar values. The documents stored are similar to
each other but do not have to be exactly the same. Document databases store documents in the
value part of the key-value store; think about document databases as key-value stores where the
value is examinable (Sadalage & Fowler, 2012). Even though the documents do not follow a
strict schema, indexes can be created and queried.
Advantages of Document Databases:


Consistency



Easy use for web-based applications



Schema-less



Easy to define



Scaling

Document Databases are good for:


Event logging



Content Management System (CMS)



Web analytics



E-commerce platforms

2.3.5.3 Column Oriented Databases. Column stores have been in development since
early DBMS days. TAXIR, a biology information-retrieval-focused application, was the first
application using column-oriented stores way back in 1969 (Vaish, 2013).
2.3.6 Graph Databases. A new kind of database called a “graph’ database has recently
emerged. A NoSQL database is a graph databases are noticeably post-relational data stores,
because they evolve several database concepts much further while keeping other attributes. They
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provide the means of storing semi-structured data but extremely connected data efficiently and
allow the user to query and traverse the connected data at a very high speed and efficiency.
Graph databases, as Figure 6 illustrates usually consist of nodes connected with directed
and labeled relationships. In property graphs, both nodes and relationships can hold arbitrary
key/value pairs. Graphs form a sophisticated network of those elements and ease the process to
model domain and real-world data. The graph is a structure close to the original structure which
is a big difference from traditional databases. Unlike relational databases, which rely on welldefined schemas to model data, graph databases are schema-free and put no constraints onto the
data structure which open more space for database architects to be creative. Relationships can be
added and changed easily, because they are not part of a schema but rather part of the actual data.
Figure 6 illustrates an example of how the nodes and relationships connect.

Figure 6. Visual Example of an actual Graph data model
Figure 7 shows that the graph involves equation vertices and edges. Vertices (Nodes) includes the

following: unique identifiers, outgoing edges, incoming edges, and key/value pairs. While the
edges (relationships) consist of: Unique identifiers, outgoing vertex (node), incoming vertex
(node), and again key/value pairs.
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Figure 7. Graph theory equation

Graph databases are based on algebraic equations while relational databases are based on
sets, graph databases are based on graph theory, a branch of discrete mathematics. A graph
database management system (henceforth, a graph database) is an online database management
system typically contains the commands that Create, Read, Update, and Delete. Graph databases
are generally built for use with transactional (OLTP) systems. Accordingly, they are normally
optimized for transactional performance, and engineered with transactional integrity and
operational availability in mind.
A graph has two things in it. There are edges (or arcs) and nodes (or vertices); the edges
are drawn as lines that connect nodes, which are drawn as dots or circles. Nodes are abstractions.
They usually (not always) model what would be an entity in a RDBMS. In fact, some of the
power of graph theory is that a node can model a sub graph. A node may or may not have
“something inside it” (electrical components) in the model; it can just sit there (bus stop) or
simply be (transition state). A node is not an object. Objects have methods and local data inside
them. Other examples of graphs are:


Schematic maps: the nodes are the bus stops, towns, and so forth.



Circuit diagrams: the nodes are electrical components.



State transitions: the nodes are the states.
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Edges or arcs connect nodes. They are drawn as lines that may or may not have an arrow
head on them to show a direction of flow when the edges have arrows, the graph is called a
“directed” graph otherwise it is called un-directed graph. They may also contain weights
denoting the strengths of the relationship between the nodes. In schematic maps, the edges are
the roads. They can have a distance or time on them. In the circuit diagrams, the edges are the
wires that have resistance, voltage, etc. Likewise, the abstract state transitions are connected by
edges that model the permitted switch paths.
In one way, edges are more fun than nodes in graph theory. In RDBMS models of data,
an unspecified single relationship between tables exists in the form of a REFERENCES clause.
In a graph database, there are multiple edges of different kinds between nodes.
At the highest level of abstraction an edge can be directed or undirected. In terms of maps, these
are one-way streets; for state transitions, this is prior state–current state pairs and so forth.
Undirected graphs is preferable since the math is easier and there is often an inverse relationship
of some sort (e.g., “employer–manager” in the case of Jose Mourinho and Jorge Valdano).
2.3.6.1 Graph Databases Pros and Cons. There are several pros and cons associated with
graph databases, the pros are a powerful data model that is not limited with any schema
constrains, connected data that have many layers and levels of details and properties, and locally
indexed inside the database architect, and easy and flexible to query. Nevertheless graph
databases do have multiple cons, too much sharding either horizontal or vertical partition of the
data inside the graph database, and a very diverse approach from relational database concept
2.3.6.2 Graph Database Domains. Many applicable industries or solution landscape can be
deployed using the graph databases, impact analysis (network, software), logistics, supply chain
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for package routing, recommendation systems (dating, social…etc.), master data management,
financial especially fraud detection.
In this section we have highlighted the main challenges in designing graph databases. To
this end, three specific challenges were targeted by this research study – data models, storage
models and index structures (Pardede & Sakr, 2011). Graph databases has attracted vast research
attention, but has still eluded strong foundations or an overarching best practice or design
principles. Research and commercial interest in graph databases is still increasing as of this
writing. As the amount of data grows and the need for identifying patterns and extracting
semantics becomes stronger, graph data management becomes an imminent challenge (Pardede
& Sakr, 2011).
2.4 Neo4j
Neo4j is the leading application of a property graph database. It is written mainly in Java
and leverages a custom storage format and the facilities of the Java Transaction Architecture
(JTA) to provide XA transactions. The Java API offers an object-oriented approach to
manipulate the nodes and relationships of the graph (Pollack; Risberg; Hunger; Brisbin; &
Gierke, 2012). Traversals are expressed with a fluent API. Being a graph database, Neo4j offers
a number of graph algorithms like: Shortest path, Dijkstra, and A* out of the box.
Neo4j integrates a transactional, pluggable indexing subsystem that uses Lucene as the
default. The index is used primarily to locate starting points for traversals. Its second use is to
support unique entity creation (Pollack; Risberg; Hunger; Brisbin; & Gierke, 2012). Neo4J
provides a web interface for statistics about the database. In the data browser, it is possible to
search for nodes by ID, or with index lookups, and with cypher queries, and switching to the
graph visualizer with the right-hand button for visually exploring the graph. The console allows
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the user to enter Cypher statements directly or issue HTTP requests. The other great advantage is
that Neo4j an open source product, hence it has a comprehensive and active ecosystem. Neo
Technology, is the company sponsoring the development of Neo4j. Neo4j also comes with a
variety of programming language drivers available. There are libraries for many programming
languages for both embedded and server deployment mode.
2.4.1 List of Programming Language Drivers. Neo4j have many addable programming
language driver that includes: PHP Cypher, Python, R Neo4J, Perl, Ruby, Node.JS, Scala, and
JavaScript.
Neo4J is considered a property graph, which is a “directed, labeled, attributed multigraph” that exposes three building blocks: nodes, typed relationships, and key-value properties
on both nodes and relationships. Another graph model is RDF Triples, which is a URI-centered
subject-predicate-object triples as pioneered by the semantic web movement. Finally there’s
HyperGraph, which is a generalized graph in which a relationship can connect an arbitrary
number of nodes (compared to the more common binary graph models) (McKnight, 2013).
Hypergraph is a generalized graph model in which a relationship (called a hyper-edge)
can connect any number of nodes. More specifically, while the property graph model permits a
relationship to have a single start and end node, the hypergraph model allows any number of
nodes at a relationship’s start and end (McKnight, 2013).
Neo4J has a declarative Cypher query language, which makes it easier to get started for
everyone who knows SQL from working with relational databases. Developers as well as
operations and business users can run ad-hoc queries on the graph for a variety of use cases.
Cypher draws its inspiration from a variety of sources:


SQL
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SparQL



ASCII-Art



Different functional programming

Cypher was built to create matching patterns in a graph that are bound to specified nodes
and relationships and allows additional filtering and indexing of the results. Cypher has data
manipulation features that allow us to modify the graph. Cypher query parts can be chained
(piped) to enable more advanced and powerful graph operations. Figure 8 depicts a cypher query
code and the results after executing this query

Figure 8. Example of Cypher code
The core concept is that the user describes the patterns to be matched in the graph and
find starting points. The Neo4J database engine then efficiently matches the given patterns across
the graph, enabling users to define sophisticated queries like “find me all the people who have
friends or co-workers who have recently bought gadget products.”, Cypher supports filtering,
grouping, and paging. Cypher allows easy creation, deletion, update, and graph construction.


Nodes: Cypher uses ASCII-art to represent patterns. Nodes are surrounded with
parentheses which look like circles, e.g. (node) .
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Relationships: The problem with the Cypher snippets is that they don’t contain
information about the relationship between the nodes. So the need for describing the
types of relationships in Cypher queries is essential (Onofrio Panzarino, 2014).



Labels and Cypher Query Language: Labels give a very convenient feature by allowing
to group our nodes. The Cypher query language is comprised of several distinct clauses.

Querying a graph involves these commands:



MATCH: Matches the given graph pattern in the graph data.



WHERE: Filters using predicates or anchors pattern elements.



RETURN: Returns and projects result data, also handles aggregation.



ORDER BY: Sorts the query result.



SKIP/LIMIT: Paginates the query result.

Updating the graph involves these commands:



CREATE: Creates nodes and relationships.



MERGE: Creates nodes uniquely.



CREATE UNIQUE: Creates relationships uniquely.



DELETE: Removes nodes, relationships.



SET: Updates properties and labels.



REMOVE: Removes properties and labels.



FOREACH: Performs updating actions once per element in a list.
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WITH: Divides a query into multiple, distinct parts and passes results from one to the
next.

Cypher Principles and Capabilities


Cypher matches patterns of nodes and relationship in the graph, to extract information or
modify the data.



Cypher has the concept of identifiers which denote named, bound elements and
parameters.



Cypher can create, update, and remove nodes, relationships, labels, and properties.



Cypher manages indexes and constraints.

Neo4j Advantages


Close to the object model



Pre materialize relationships



Traversals in linear time



Sparse, heterogeneous data and schema free



Local queries



User Interface is super friendly

2.5 Neo4J Applications
The graph data model in general and Neo4J specifically renowned for the power and
flexibility, and its essential expressiveness. The graph databases application in a real-world
problem can be seen as the fast performance of the queries and responsiveness helps
organizations with their online transactional systems. Graph databases also ideal for quick
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development cycles, finally Neo4J is “Enterprise” ready in terms of capabilities, performance,
and characteristics.
2.5.1 Social Science Application. Social applications allow organizations to gain
competitive and operational advantage by leveraging information about the connections between
people, together with discrete information about individuals, to facilitate collaboration and flow
of information, and predict behavior.
As Facebook’s use of the term social graph implies, graph data models and graph
databases are a natural fit for this overtly relationship-centered domain (Robinson; Webber; &
Eifrem, 2013).
By understanding who interacts with whom, how people are connected, and what representatives
within a group are likely to do or choose based on the aggregate behavior of the group, Neo4J
can generate tremendous insight into the unseen forces that influence individual behaviors.
2.5.2 Master Data Management. Master data is data that is critical to the operation of a
business, but which itself is non-transactional. Master data includes data concerning users,
customers, products, suppliers, departments, geographies, sites, cost centers, and business units.
Graph databases don’t provide a full MDM solution; they are, however, ideally applied to
the modeling, storing, and querying of hierarchies, master data metadata, and master data
models. Such models include type definitions, constraints, relationships between entities, and the
mappings between the model and the underlying source systems (Robinson; Webber; & Eifrem,
2013).
2.5.3 Logistics and Supply Chain. Logistics related applications of graph databases
range from calculating routes between locations in an abstract network such as a road or rail
network, airspace network, or logistical network to spatial operations such as find all points of
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interest in a bounded area, find the center of a region, and calculate the intersection between two
or more regions (Robinson; Webber; & Eifrem, 2013).
Logistics operations depend upon specific data structures, ranging from simple weighted and
directed relationships, through to spatial indexes that layout multidimensional attributes using
tree map data structures.
2.5.4 Recommended Systems. Effective recommendations are a prime example of
generating end-user value through the application of an inferential or suggestive capability.
Recommendation algorithms establish relationships between people and things: other people,
products, services, media content—whatever is relevant to the domain in which the
recommendation is employed (Robinson; Webber; & Eifrem, 2013). As nodes and relationships
are created in the system, they can be used to make recommendations like “when invoicing this
item, these other items are usually invoiced.” Or, it can be used to make recommendations to
travelers mentioning that when other visitors come to Barcelona they usually visit Antonio
Gaudi’s creations (Sadalage & Fowler, 2012).
2.5.5 Fraud Detection Systems. The principle is quite simple: in many cases, the fraud
of a particular nature is not defined by one transaction only, but by a chain of transactions that
have their specific characteristics and that need to be compared to one another to see if they
really do constitute a case of fraud. That are based on linked intelligence. Unlike the traditional
relational database technologies which requires modeling the graph above as a set of tables and
columns, and then carrying out a series of complex joins and self joins. This type of queries are
very complex to build and expensive to run on a traditional RDBMS. Scaling them in a way that
supports real-time access poses significant technical challenges, with performance becoming
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exponentially worse not only as the size of the ring increases, for that reason Graph databases
have emerged as an ideal tool.
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CHAPTER 3
RESEARCH DESIGN AND PROCEDURES
Based on the research question and purpose, the study of this research follows an
exploratory approach in which a mixed method is established for examining and evaluating the
prototype. A mixed method encompasses the quantitative and qualitative approaches as
subjective and objective procedures (Mahmud, 2006). In a mixed method, the study of this
research tends to build the knowledge claim on practical arguments such as outcome-directed, or
problem-centered (Creswell, 2003). In a quantitative approach, the knowledge is developed via
the implementation of postpostivist claims. Examples include shrinking to the questions of this
research, applying measurement and remark and testing the theory. Postpostivist viewpoint is the
thinking after positivism, disputing the typical certainty of the knowledge of our research
(Creswell, 2003).
Since the study solution of this research provides an interactive system to accelerate
information retrieval, mixed method can be absolutely relevant to such system. It is forceful and
practical everywhere in the computing area where numerous jobs may be engaged in an
application. The advantages of mixed method include presenting a huge data, and practical
environment. Also, it provides portability (Mahmud, 2006).
In this thesis, a proof of concept, also known as a vertical prototype, implements a slice
of application functionality from the user interface through all the technical services layers. It
works as a real system at all levels of the system implementation. It is developed to validate the
concept of the proposed architectural approach and to evaluate the proposed database schema.
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To make the results meaningful, such prototype is constructed by using production tools
in a production-like operating environment. Agile development projects sometimes refer to a
proof-of-concept prototype as a “spike.” (Alan, 1993).
A throwaway prototype is built to answer questions, resolve uncertainties, and improve
requirements quality (Alan, 1993). It emphasizes quick implementation and modification over
robustness, reliability, performance, and long-term maintainability. For this reason, low-quality
code is not allowed from a throwaway prototype to migrate into a production system (Beatty,
Wiegers, 2013).
In contrast to a throwaway prototype, an evolutionary prototype provides a solid
architectural foundation for building the product incrementally as the requirements become clear
over time (McConnell, 1996).
Agile development provides an example of evolutionary prototyping. Agile teams
construct the product through a series of iterations, using feedback on the early iterations to
adjust the direction of future development cycles. This is the essence of evolutionary
prototyping.
In contrast to the quick-and-dirty nature of throwaway prototyping, an evolutionary
prototype must be built with robust, production-quality code from the outset. Therefore, an
evolutionary prototype takes longer to create than a throwaway prototype that simulates the same
system capabilities. An evolutionary prototype must be designed for easy growth and frequent
enhancement, so developers must emphasize software architecture and solid design principles.
There’s no room for shortcuts in the quality of an evolutionary prototype (McConnell, 1996).
Table 2 represents the difference between the two prototype approaches.

40
Table 2.
Difference between approaches
Throwaway
Mock-up



identify user/functional

Evolutionary


requirements


locate the missing

Implement main users
requirements



functions

Apply the extracted
requirement into the
system/architect



Explore user interface



approaches

Accommodate the system to
continuous changing business
requirements

Proof of Concept



Demonstrate technical



feasibility

Implement and grow core
multi-tier functionality and
communication layers.



Evaluate performance



Implement and optimize core
algorithms



Acquire knowledge to



Test and tune performance.

improve estimates for
construction.

Figure 9 explains several possible ways to combine the various prototypes. For example, the
knowledge gained from a series of throwaway prototypes can be used to refine the requirements,
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which might then implement incrementally through an evolutionary prototyping sequence
(Beatty; Wiegers, 2013).

Figure 9. Incorporation of prototyping into the software development process

3.1 The Prototype Model
In the study of this research, the prototyping model is an evolutionary procedure that
replaces some of the Software Development Life Cycle’s phases. The purpose of this process is
based on the developer, users, and customers’ communication channel (Galin, 2004). The user
receives the prototypes to examine it and provides feedbacks. The developer keeps on
developing a more advanced prototype. Again, the user receives it to examine the new
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developments and provides further feedbacks. Such procedure is repeated either until the study
solution satisfies the specified requirements or the prototyping purpose is accomplished.
Thus, the essential features of the prototyping process can be identified by a set of
characterization. This set of characterization consists essentially of several iterative cycles. The
initial prototype is an executable software model that is constructed based on either an initial
selection of functions or based on user’s needs that have been identified. A demonstration or
actual usage of the prototype allows review by users. User’s suggestions, criticisms and
enhancements result in revision of the prototype. This cycle is continued for each revised
version. The prototyping process is completed when the desired objective is attained (El-Bathy,
2011).
Evolutionary prototyping is a procedure that makes a prototype the eventual operational
system such that recreation or redevelopment of some of the system’s pieces may be needed by
applying other methodologies (Anton, A. & Carter, R. & Earp, J. & Williams, L., 2001).
Neumann and Jenkins (1982) characterize a prototyping as a four step, iterative
procedure involving users and developers:
1. User’s basic needs are identified;
2. A working prototype is developed
3. The working prototype is then implemented and used
4. The prototyping system is revised and enhanced
This process undergoes several iterations and both steps three and four are repeated until
the user accepts the system.
Maner (1997) states that prototyping is a model that represents a designed application
which can be changed or enhanced. The application’s functions and interfaces are contained
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within the prototyping. The processes of Maner’s prototyping are subject to many variations.
Maner (1997) shows these processes in Figure 10 as follows:
1. Analyzing the customers or the users’ requirements
2. Clarifying the initial requirements by building a low fidelity prototype
3. Conducting iteration processes in order to re-identify, re-plan, re-examine the level of
the users’ satisfaction based on their needs.
4. Freeze the specifications
5. Completing the system’s development

Figure 10. Walter Maner's Iterative Prototype Process

44
3.2 The Prototype High Level Use Case
Figure 11 reflects the general picture of Graphical Database architect (GDA) for Clinical
Trial high level use case. The diagram defines the main activities of the system. The component
of the diagram explains the interaction between the user/management and the system.

Register

Add/Approve User

Login
Add/Approve User
Search by Diseases

Search by Intervention
Update Clinical Trials
Search by Dietary Supplements

User

Search by Sponsor

Clinical Trials
Admin Admin

Create New Clinical Trials

Search by Location

Figure 11. High Level User Cases

3.3 Prototype Requirements
User Interface (UI) is built as a web interface on Windows 8 platform. This UI forms the
starting point of the Graphical Database architect (GDA) for Clinical Trial, and further
requirements will be built onto it. The User Interface is then added to the prototype requirements
Specification document.
The Graphical Database architect (GDA) for Clinical Trial is intended to permit the
development of a set of means that address performance, capabilities, and functionality concerns.
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The prototype User Interface (UI) is identified as abstract of front end interfaces that represent
the backend of the architect of the model and its implementation. The architecture operates as a
model that can be used for showing the establishment of several instances of the system. It
enables implementing the services by several application components. In this study, the
Evolutionary Rapid modeling is a process where model the data aspects of a system iteratively
and incrementally, just like all other aspects of a system, to ensure that the database schema
evolves in step with the application code.
Table 3.
The GDA prototype functions
Functionality

Type

Register

Essential

Login

Essential

Search for trial by diseases

Essential

Search for trial by intervention

Essential

Search for trial by dietary supplement

Essential

Search for trial by sponsor

Essential

Search for trial by location

Essential

Create new clinical trial

Essential

Updated an existing clinical trial

Essential
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3.4 GDA for Clinical Trials Architecture Prototype
This section explains the prototype architecture of Graphic Database Architecture (GDA)
for Clinical Trials. Figure 12 describes the three-tiered web-enabled prototype architecture.

Figure 12. Neo4j Architecture for GDA prototype
Portrays the core components involved in a running Neo4j in server mode, along with a
client accessing the server using the standard, and REST API. The Neo4j server is itself simply a
JVM-based application. Under the covers, it provides its functionality by wrapping an
appropriate instance of the “GraphDatabaseService” interface (EmbeddedGraphDatabase or
HighlyAvailableGraphDatabase), exposing the functionality to the outside world through a welldefined REST interface. To be able to listen to and react to REST requests made to the server by
clients, all Neo4j server instances will start up an embedded web server.
Neo4j can be run in two different modes:


An embedded database in a Java application



A standalone server via REST
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In any case, this choice does not affect querying and working with the database. It's an
architectural choice driven by the nature of the application (whether a standalone server or a
client server), performance, monitoring, and safety of data (Panzarino, 2014).
3.5 Tools for the Prototype Implementation:
This section describes software interfaces and development tools that are used for the
prototype. These tools are compatible with windows environment, in both terms of designing and
coding. In terms of design, the Microsoft Visio is used to design the Prototyping Model and
Prototyping Architecture.
3.5.1 Software Interfaces. The following is a list of software used:


Operating System – Microsoft Windows 8



The backend server is a Java web application, running an embedded Jetty servlet
container.



Database Server – Neo4j
3.5.2 Development Tools. The Tools that are used for prototype implementation



Graph Gist



Graph ETL



Neo4j Community edition

3.6 The Prototype Evaluation Criteria
The remainder of this subsection describes the walkthrough methodology. Walkthrough
evaluates the GDA for Clinical Trials architecture of extensive, complicated, and heterogeneous
system. Walkthrough supports dynamic development such that the architectural demonstration
can be recommended precisely during walkthroughs with the project’s stakeholders (Haynes &
Skattebo & Singel & Cohen & Himelright, 2006).
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The models based on cognitive architectures have been used in human-computer
interaction in three ways: to predict task performance times and errors, to assist users in task
performance, or to substitute users in testing (John, 1998; Ritter et al., 2000)
An integrative approach to UI design is an approach based on the principles that unify cognition
and other elements of interactive behavior. These principles also unify theories on interactive
behavior and their methodology with UI design (Kljajevic, 2008)
An informal walkthrough is mainly a helpful method for separating and determining
ambiguity that is related to unclear system specifications. A formal walkthrough can be modified
to develop a recursive evaluation process as the informal walkthrough advances and produces
detailed outputs (Haynes & Skattebo & Singel & Cohen & Himelright, 2006).
The techniques of walkthrough are approved as experimental assessment approaches to
evaluate system application usability (Rowley & Rhoades, 1992). A cognitive structured
walkthrough method theoretically examines the procedure based on a number of questions.
These questions help the interface designer concentrate on the important characteristics for
solving the theory’s problem (Lewis & Poison & Wharton & Rieman, 1990).
A groupware walkthrough presents an independent adaption of cognitive walkthrough
method. It is a technique that is adjusted for groupware usability inspection. This technique is
also applicable for real work situation. It is usable in developing software system in its early
phases. It reveals the system usability problems (Pinelle, & Gutwin, 2002).
For a single user of a software system, cognitive walkthrough is considered a general
evaluation methodology since it enables the software evaluation during its early development’s
phases. Cognitive walkthrough also doesn’t need a prototype that is functioning. It describes the
system’s users along with their knowledge. It also depicts the system user’s roles. Via a
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walkthrough, the evaluators walk through these roles to ensure that the user performs the exact
role based on the prototype (Pinelle, & Gutwin, 2002).
The walkthrough methodology of cognitive and groupware keep information of the
system’s users and their tasks externally. The designer of the system interface is not responsible
for the other details about the work situation. The evaluators of the cognitive and groupware
walkthrough methodologies are able to briefly deliver information about the tasks without any
details (Pinelle, & Gutwin, 2002).
The walkthrough technique that is developed by groupware can be performed the same as
the techniques of discount usability at a moderate and low cost. Multi-user systems can be
evaluated as well through groupware walkthrough technique in conjunction with groupware
heuristic evaluation at low cost. In the initial development process, groupware walkthrough
method is used to enable the system’s developers to apply formative evaluation during the design
phase. During the system evaluation phase, the walkthrough technique guarantees the discovery
of the majority of the problems related to the automatic usability such that a located examination
can concentrate on the problems of the highest level. The examiners will be able to evaluate the
interfaces that are related to real roles and real customers (Pinelle, & Gutwin, 2002).
The study of this research plans to carry out a walkthrough technique that examines the
prototype. The walkthrough method provides a comprehensive evaluation the phases of the
research. These phases of this thesis includes the planning problem identification, the research
planning, the literature review, the research proposed solution, and the research testing.
The walkthrough participants of this study would be clinical trials investigators, medical
professionals, pharmaceutical professionals and students. The aim of the walkthrough is evaluate
the prototype to ensure that it satisfies requirements of this research. They will verify that the
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solution is visualized correctly. They also will have the chance to verify that the documented
findings solve the research problem.
3.7 The Research Analysis
The analysis of this research is planned to review recent knowledge about Graphical
Database Architecture for Clinical Trials, discover knowledge gaps, and identify future research
target. The research analysis results are projected to help solve the problems of clinical trials by
accelerating information retrieval processes in Medical and Healthcare organization.
The analysis reviews recent literature about the Medical and Healthcare industries’
information retrieval lifecycle. In general, the analysis goal is identifying the required
information for accelerating information retrieval processes based on the alignment between IT
and the business strategy. The goals of the analysis provide and define:
1. The main knowledge gaps in the business
2. The key strategies to accomplish the goals
3. The research requirements and limitations
4. The publishing and newspaper users of the research solution
5. The knowledge gaps affect the research analysis.
The conceptual models are the core of the prototype development iteration and these
models should be integrated in the analysis stage of a lifecycle model (El-Bathy & Gloster,
2012). The study of this research has focused on the following:
3.7.1 The Method of Data Collection. In data collection step, data from Clinical Trials
website is collected. The collected data is stored into database for additional process. The
collected data from Clinical Trials site is semi-structured data uses Neo4j. Clinical Trials data is
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a semi-structured data as Figure 13 illustrates data that doesn't reside in a relational database but
that does have some organizational structure properties that make it easier to analyze.

Figure 13. Data Types Landscape
In this research using Clinical Trials data is used to build the ontology of the graphical
database. The ClinicalTrials.gov results database was launched in September 2008 to implement
Section 801 of the Food and Drug Administration Amendments Act of 2007 (FDAAA 801),
which requires the submission of "basic results" for certain clinical trials, generally not later than
1 year after their Completion Date.
The submission of adverse event information was optional when the results database was
released but became required in September 2009. Results information for registered and
completed studies is submitted by the study sponsor or principal investigator in a standard,
tabular format without discussions or conclusions. The information is considered summary
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information and does not include patient-level data. The results information that is submitted
includes the following:


Participant Flow. A tabular summary of the progress of participants through each
stage of a study, by study arm or comparison group. It includes the numbers of
participants who started, completed, and dropped out of each period of the study
based on the sequence in which interventions were assigned.



Baseline Characteristics. A tabular summary of the data collected at the beginning
of a study for all participants, by study arm or comparison group. These data include
demographics, such as age and gender, and study-specific measures (for example,
systolic blood pressure, prior antidepressant treatment).



Outcome Measures and Statistical Analyses. A tabular summary of outcome
measure values, by study arm or comparison group. It includes tables for each
prespecified Primary Outcome and Secondary Outcome and may also include other
prespecified outcomes, post hoc outcomes, and any appropriate statistical analyses.



Adverse Events. A tabular summary of all anticipated and unanticipated serious
adverse events and a tabular summary of anticipated and unanticipated other adverse
events exceeding a specific frequency threshold. For each serious or other adverse
event, it includes the adverse event term, affected organ system, number of
participants at risk, and number of participants affected, by study arm or comparison
group. Then ClinicalTrials.gov organizes information for each registered study as an
integrated unit, displaying the study protocol information and, if available, the
corresponding results information on the same page under different tabs. (Clinical
Trials Website)
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3.7.2 XML Data. The eXtensible Markup Language (XML) is increasingly finding
acceptance as a standard for storing and exchanging structured and semi-structured information
over internet (Conrad, 2000)
A conceptual model of semi-structured data deals with high level representation of the
candidate application domain in order to capture the user ideas using rich set of semantic
constructs and interrelationship thereof. Besides some similar characteristics of structured
(classical) database system, several crucial characteristics are added complexity for the design of
semi-structured database system. For effective design of such system, the intended conceptual
model must be capable to adopt the rapidly data evolving characteristics, representation of
irregular and heterogeneous structure, hierarchical relations along with the non – hierarchical
relationship types, cardinality, n – array relation, ordering, representation of mixed content etc.
(Necasky, 2006). Examples of Semi-structured data:


Forms



Classified ads



Jobs postings



Tax reports



XML documents



Emails

Figure 14 exemplify how to expose many business opportunities for leveraging semistructured data to help extract business value and visual representation of the relationships
between data elements to build useful systems based on these opportunities:


Call center transcripts



Technician repair notes
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Medical history



Billing history



Loan applications

Figure 14. Representation of Relationships
3.8 Preparing Clinical Trials Data Ontology
Key data elements fields that should be included in each clinical trial study. These data
elements is called nodes in the graphical databases landscape because they are considered key to
the clinical study.
Table 4.
The clinical trials data ontology (CTDO)
Data Elements
Sponsor

Definition
The name of primary organization that oversees implementation of
study and is responsible for data analysis
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Table 4.
Cont.
Collaborators

Providing support, including funding, design, implementation, data
analysis and reporting. The data provider is responsible for
confirming all collaborators before listing them. Provide up to 10 full
names of collaborating organizations.

Oversight

Indicate whether this trial includes an intervention subject to US
Food and Drug Administration (FDA)

Protocol Outcome

The written description of a clinical study. It includes the study's
objectives, design, and methods. It may also include relevant
scientific background and statistical information.

Enrollment

The number of participants in a clinical study. The "estimated
enrollment" is the number of participants that the researchers need for
the study.

Arm Group

A group or subgroup of participants in a clinical trial that receives
specific interventions, or no intervention, according to the study
protocol. This is decided before the trial begins.

Intervention

A process or action that is the focus of a clinical study. This can
include giving participants drugs, medical devices, procedures,
vaccines, and other products that are either investigational or already
available. Interventions can also include noninvasive approaches
such as surveys, education, and interviews.

Text Block

Include the text that describe the intervention
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Table 4.
Cont.
Eligibility

Summary criteria for participant selection. The preferred format
includes lists of inclusion and exclusion criteria

Contact

Person providing centralized, coordinated recruitment information
for the entire study.

Investigator

A researcher involved in a clinical study. Related terms include Site
Principal Investigator, Site Sub-Investigator, Study Chair, Study
Director, and Study Principal Investigator.

Address

Mailing address for the board, including street address, city, state or
province, postal code, and country

Facility

Full name of the organization where the protocol is being conducted

Location/country

Location of the facility or organization that carrying out the clinical
trial study

Links

A Web site directly relevant to the protocol may be entered, if
desired. Do not include sites whose primary goal is to advertise or
sell commercial products or services

References

Citations to publications related to the protocol: background and/or
results. Provide either the PubMed Unique Identifier (PMID)

Responsible Party

1. the sponsor of the clinical trial or
2. the principal investigator of such clinical trial

Browse

Browse the content of a clinical trial
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Table 4.
Cont.
Group

For observational studies specify the predefined participant groups
(cohorts) to be studied, corresponding to Number of Groups specified
under Study Design

Milestones

Definition: Any specific events or time points in the trial when the
numbers of participants are reported may be added

Period

Discrete stages of a clinical trial during which numbers of
participants at specific significant events or points of time are
reported

Participants Flow

Progress of research participants through each stage of a trial in a
tabular format, including the number of participants who dropped out
of the clinical trial.

Measure Category

Name of distinct category for a baseline measure, if reporting
categorical data.

Measure

Name and description of a characteristic measured at the beginning
of the trial

Baseline

A table of demographic and baseline data for the entire trial
population and for each arm or comparison group

Analysis

Explanation of how the number of participants for analysis was
determined

Results outcome

trial results after the trial is completed
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Table 4.
Cont.
Vocabulary Term

Default value for Source Vocabulary Name to be applied to all
adverse event terms

Certain Agreements

Information certifying whether there exists an agreement between the
sponsor or its agent and the principal investigators

Point of contact

for scientific information about the posted clinical trial results

Clinical Study

A research study using human subjects to evaluate biomedical or
health-related outcomes. Two types of clinical studies are
Interventional Studies and Observational Studies.

3.9. Limitations of Neo4j database:
In this section the limitations of the tool used in this research study of this research
(Neo4j) is listed to be the direction that the scientists have to solve and deal with. These
limitations are:


Add a data cleaning and data mining capabilities to the architecture of this research



The concept of graph databases is a new discipline to use in clinical informatics systems



Truthful recourses needed for installation and configuration



Literature review articles



Most of the applications that use Neo4j are used in small number of areas (Logistics, social
media, recommendation systems, and master data management).



Thus Neo4j is flexibility of not having a defined database schema can cause problems that
could hinder the efficiency of the query results.
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The graphical database Neo4j necessitate high advanced technologies in terms of
knowledge in the tool, and hardware requirements to function properly and perform up to
expectation.
Graph databases software is immature compared to the traditional RDBMS. The free
versions available online don’t provide the comprehensive capabilities for full scale projects.
Moreover, the online accessible platforms such as Graph Gist, Graph ETL, and Neo4j
Community edition do not provide a complete set of big data components.
In addition, Neo4j software installation instructions are not direct specifically on
Windows OS or Mac OS as there isn’t an executable installer for these tools. For example, Neo4j
has many versions. Each version requires a set of instructions and compatibility.
In conclusion also, Neo4j database can’t partitioned, this suggest a dilemma to address;
that will end up with a whole dataset in one server. This situation will put Neo4j scalability on
test as to overcome this obstacle to scale vertically every time a space added on the server for
more data.
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CHAPTER 4
RESEARCH FINDINGS
The research aims to deliver a conceptual solution to a very specific problem instance in
the area of clinical information retrieval, accompanied with new graph database solution to yield
unique features that are not available in traditional relational database management systems
(RDBMS).
4.1 Analysis
The research question and problem of this thesis is important to the medical and
healthcare industries. The research question focuses on the integration of search engine,
information extraction, information retrieval, and data management to determine the best
treatment for a certain disease. The research problem focuses on the development and
implementation of a Graphical Database Architecture for Clinical Trials.
4.2 Theoretical Solution
By applying the mechanisms of the research design, the study of this research is required
to construct an initial theoretical scenario related to the subject of research the clinical trials
(CT). This theoretical scenario provides an adequate scheme for the research.
This hints to a theoretical story about the events, structures and phases occur during a
clinical trial. The outcome is a path in determining what data to collect and the approaches to
analyze the data. This theoretical model of clinical trials (CT) scenarios provides a distinctive
knowledge that can be used to improve application of analyzing and mining the clinical trials
(CT) data. Our theoretical model emphases on assertion of achieving the goal of the study of this
research in terms of outcome and efficiency.
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The theoretical model in Figure 15 below demonstrates the routine scenario of clinical
trials (CT) process. At the beginning clinical trials (CT) is a crucial link between the research
and development (R&D) chain in the health sector. There are three crucial element must
achieved in every clinical trial study, these elements are: Quality, Safety, and Efficacy.
The starting point of the clinical trials (CT) process is when the scientists or researchers
begin to analyze the disease and investigate a possible treatment. Preclinical trials then establish
initial safety and effectiveness before testing on human beings. These tests are often done in the
laboratory, using test tubes research. After the preclinical trials, the next step is to check for
safety (Phase I) by investigating treatment safety and research how it works and behaves in the
human body. Usually this process takes between weeks and months and involve less than 100
participants. Phase II includes testing the efficacy of the treatment on hundreds of participants
who have the disease, this phase is important to investigate side effects and risks. The timeframe
of (Phase II) takes sometime up to several years. The next step (Phase III) is a very important
step before seeking final approval. At this point the study pursues to establish benefit-risk, the
right patients, and the best way to manage side effects of the treatment. This time the tests will be
conducted on 1000’s of participants to make sure that all aspects of the study are follow the
regulatory constraints.
Now the treatment results are confirmed and met the safety, quality, and efficacy
measures. The governing body or regulators (in USA case Food and Drug Administration FDA
is the regulator) after reviewing all the previous phases grant their approval and authorize the
treatment/drug for use.
In Phase IV studies are concluded after the drug or treatment has been marketed to collect
information on the drug's effect in numerous patients and any side effects associated with use.
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Clinical Trials
(Phase I,
Phase II,
Phase III)

Getting
Started

the scientists or
researchers begin by
analyzing the disease
and investigating a
possible treatment






Check for Safety
Check for efficacy
Check for Quality
Confirm Results of the
tests

Approval

Phase IV

Food and Drug
Administration (FDA)
Approval

studies are concluded
after the drug or
treatment has been
marketed to collect
information on the
drug's effect in
numerous patients

Figure 15. Visual Scenario of a Clinical Trial (CT)
4.3 Visual Representation of Methodology Findings
Base on the data elements extracted in Chapter 3, a visual representation for the Clinical
Trial is developed. This visual depiction going to serve as a conceptual roadmap to incorporate
all these data elements in the Graphical Database Architecture (GDA) for Clinical Trials (CT).
Six main “graphical” groups in our visual representation are identified to constitute Clinical Trial
Ontology (CTO):
4.3.1 First Group: Study Type:
This data element describes nature of the investigation:
Interventional or clinical study: the starting point of the study illustrated in Figure 16 when
individuals are assigned by an investigator based on a protocol to receive specific interventions
(diagnostic, therapeutic…etc.).
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Observational study: where biomedical results are assessed in pre-defined groups of
individuals. Subjects in the study may receive diagnostic, therapeutic, or other interventions. But
the key difference is the investigator didn’t assign a precise intervention for the study.
Expanded Access: Expanded Access records are used to index all types of non-protocol access
to experimental treatments, including protocol exception, single-patient IND (Investigational
New Drug), treatment IND, compassionate use, emergency use, continued access and parallel
track.

Study Type

Clinical Trial
Study

Observation
Study

Expanded Access

Patient
Registry

Figure 16. Study Type Label in the Clinical Trial Ontology (CTO)

4.3.2 Second Group. Recruitment: All Studies: showed in Figure 17 Regardless if they
are recruiting new participants or not
Open Studies: Studies that are currently recruiting participants, will be recruiting participants in
the future, or involve drugs that are available for expanded access. Recruitment statuses for open
studies are:


Recruiting
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Not yet recruiting



Available for expanded access

Closed Studies: Clinical studies that are no longer recruiting participants for various reasons (i.e.
the study is completed). Recruitment statuses for closed studies are:


Study results



Study by topic



Locations



Secondary data elements

Recruitment

All Studies

Open Studies

No longer
available

Active

Closed Studies

Completed

`

Enrolling by
invitation

Withdrawn

No longer
available

Active

Completed

Terminated

Suspended

Approved

Temporarily
not available

Figure 17. Recruitment Label in the Clinical Trial Ontology (CTO)

4.3.3 Third Group. Study Results: this label for clinical study results that were posted
in the ClinicalTrials.gov results database. Figure 18 explain three main types:


All Studies



Studies with Results



Studies without Results
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Study Results

All Studies

Studies with
Results

Studies without
results

Figure 18. Study Result Label in the Clinical Trial Ontology (CTO)

4.3.4 Fourth Group. Study by topic: In Figure 19 illustrate the following:
Conditions: describe a specific disease, disorder, syndrome, illness, or injury that is being
studied.
Interventions: describe the process or action that is the focus of a clinical study. This can include
giving participants drugs, medical devices, procedures, and vaccines.
Title Acronym: the study title acronym or an exact phrase from the brief or official title of the
study.
Outcome Measures: a measurement decided on in advance that is used to determine the effect of
interventions on participants in a clinical trial.
Sponsor and Collaborators: this specify the Sponsor (Lead) or Collaborator. A sponsor is the
organization or person (a Sponsor-Investigator) who oversees the clinical study and is
responsible for analyzing the study data. While a collaborator is an organization other than the
sponsor that provides support for a clinical study.
Sponsor (Lead): Use this field to specify the Sponsor (Lead). A sponsor is the organization or
person (a Sponsor-Investigator) who oversees the clinical study and is responsible for analyzing
the study data
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Study IDs: a clinical study by an identification number. Every clinical study is associated with
identification numbers assigned to the clinical study protocol by the sponsor, funders.
ClinicalTrials.gov assigns a ClinicalTrials.gov Identifier, or NCT Number, a unique
identification code given to each clinical study registered on ClinicalTrials.gov. The format is the
letters "NCT" followed by an 8-digit number (for example, NCT00000568).

Study by Topic

Study ID

Sponsor/
Collaborators

Outcome
Measures

Lead Sponsor

Condition

Intervention

Title Acronym

Figure 19. Study by Topic Label in the Clinical Trial Ontology (CTO)

4.3.5 Fifth Group. Locations exemplified in Figure 20:
Location Terms: to identify a specific city (such as New York) or facility (such as the Mayo
Clinic), enter it as a location term.
Country/State: Studies are often conducted in many locations around the world.
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Study Type

State

Country

Location Terms

Figure 20. Study type label in the clinical trial ontology (CTO)
4.3.6 Sixth Group. Secondary Criteria visualized in Figure 21:


Gender



Age



Clinical Trial Phase



Funding Type



Safety measurement



Clinical trial adding date: is the date that summary clinical study protocol information
was first submitted to the registry



Clinical trial update date: is the most recent date that changes to study information were
submitted to the registry
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Secondary Criteria

Clinical trial
update date

Clinical Trial
study adding
date

Safety
Measurement

Funder Type

Gender

Age Group

Clinical Trial
Phase

Figure 21. Secondary criteria labels in the clinical trial ontology (CTO)
4.4 Setting GDA for Clinical Trials Environment
This section describes the setup of the required software for creating and running the
GDA. This section contains the following:
As discussed earlier in the research, Neo4j offers flexibility of two modes to start Neo4j.


An embedded database in a Java application



A server mode that facilitate REST

As discussed in the research Neo4j is coded primarily in Java and leverages a custom storage
format and the facilities of the Java Transaction Architecture (JTA) to provide XA transactions.
The Java application program interface (API) coded in an object-oriented way of working with
the nodes and relationships of the graph.
4.4.1 Embedded Database in a Java Application. In embedded mode, Neo4j is used by
any client code that’s capable of running within a Java Virtual Machine (JVM). The advantage is
the embedded mode can be used directly with Java clients As Figure 22 shows, which make
direct connection with the core Java Neo4j libraries. The other way is by adding an additional
language-specific (i.e. JavaScript, Ruby) and frameworks provided for most JVM-based
languages.
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Typical Neo4j’s
Java library

Java Virtual
Machine (JVM)
framework

Java code

Java Virtual
Machine (JVM)
extended
languages (i.e
JavaScript)

Figure 22. The Flow of Embedded Neo4j Server
Embedded mode requires JAR files to be bundled or made available to the application
when it starts up. Then the application is going to gain access to the Neo4j database by executing
an instance of the GraphDatabaseService interface. Afterwards the application use this reference
to interact with Neo4j, using all of the available APIs. While EmbeddedGraphDatabase class
usually is used for a single machine setup; theHighlyAvailableGraphDatabase class is used for a
multiple application setup.
4.4.2 Embedded Graphical Database. First of all, to create a database, a
GraphDatabaseFactory class is needed,
GraphDatabaseFactory graphDbFactory = new GraphDatabaseFactory();
Then
GraphDatabaseService graphDb = graphDbFactory

.newEmbeddedDatabase("data/CTdb");
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4.4.3 Server Mode. In server mode, the client code work together with Neo4j’s server
through the HTTP protocol that includes the REST API. First REST API is a web services are
purpose-built web servers that support the needs of a site or any other application. Client
programs use application programming interfaces (APIs) to communicate with web services. An
API exposes a set of data and functions to facilitate interactions between computer programs and
allow them to exchange information. As depicted in Figure 23, a Web API is the face of a web
service, directly listening and responding to client requests (Masse, 2011).

Figure 23. REST Web API
Neo4j server mode offers the option to extend REST functionality when required. The
REST API can be used with a HTTP-enabled client, and another option is using one of the
remote REST client APIs available for a variety of different languages and frameworks.
4.5 Demonstration of Concept
4.5.1 Graphical Database Architecture (GDA)


GDA’s Neo4j Dashboard



GDA Data browser



GDA Power tool console



Index console



GDA’s Neo4j embedded server Information details
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4.5.1.1 Neo4j Dashboard for GDA. The Dashboard in Figure 24. The Main Dashboard of
Neo4j delivers a quick monitoring of database content and activity, convenient summary of Key
Performance Indicators (KPI) estimate of node, relationship, indexes and property numbers.

Figure 24. The Main Dashboard of Neo4j
4.5.1.2 GDA Data browser. The Data browser tab provides two views for exploring the
graph. The default inspection view displays details about nodes, relationships and property
values. The data browser in Figure 25 is a convenient tool for easy data creation and
manipulation. Also anther Data browser function is the ability to view is a simple graph
visualization.
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Figure 25. Neo4j’s Data Browser for GDA


Enter a Cypher query to view results



Inspect nodes, relationships and property values



Node and relationship results are clickable buttons


Enter a Cypher query to view results



Inspect nodes, relationships and property values



Node and relationship results are clickable buttons



Enter a Cypher query to view results



Inspect nodes, relationships and property values



Node and relationship results are clickable buttons



Enter a Cypher query to view results



Inspect nodes, relationships and property values



Node and relationship results are clickable buttons



Enter a Cypher query to view results



Inspect nodes, relationships and property values



Node and relationship results are clickable buttons
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4.5.1.3 GDA Power tool console. The shell illustrate in Figure 26 is a command-line shell
for running Cypher queries. There’s also commands to retrieve information about the database.

Figure 26. Neo4j Power Tool Console
4.5.1.4 Index console. This interface illustrated in Figure 27 create and remove indexes
from database. As discussed earlier, Neo4j has two types of indexes, node and relationship
indexes. With node indexes, a specific nodes (i.e. Clinical Trial’s National identification number
NCT) can be found, and relationship indexes is to create and archive the relationships of these
nodes. Although the index console is not capable of creating more complex structures for big
enterprise datasets which require to facilitate Neo4j REST client (REST API from Java).
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Figure 27. Neo4j Indexing tool for GDA
4.5.1.5 Neo4j Embedded Server. This tool is important to maintain and manage the
Neo4j database backend. It provides several important information, for example in Figure 28
Information about the sizes of the different parts of the Neo4j graph store:


Neo4j cache, transactions, store file sizes, configuration, and diagnostic of the DB status.



Information about the interface of MBean (included in Java Platform)



Java logging record



Java implementation information

Figure 28. GDA’s Neo4j Embedded Server Information
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CHAPTER 5
CONCLUSION & FUTURE RESEARCH
This thesis has laid the groundwork for a graphical database platform for clinical trials
(CT) data and has leveraged it to investigate multiple useful and high impact aspects of graph
theory. The thesis discusses the strengths and weaknesses of the graph databases, specifically
Neo4j. Also in this chapter, the researcher provides the recommendations of the study of this
research. Graph databases represents a truly significant structures. The technology aspect of
graph databases especially (Neo4j) is here, open and available to all in the form of the modern
graph database.
Graph databases algorithms and analytical techniques are sophisticated but not difficult to
use, the need is to comprehend how to apply these new technologies to attain any research
objectives. Modeling with graphs, graph database architecture, designing and implementing a
graph database solution, and applying graph algorithms to complex business problems is the way
to build a unique information systems.
5.1 Contribution Summary
This thesis adds to the field of health informatics, database management and big data by
applying an innovative model and new way of handling semi-structured data. The new concept
try to introduce a dynamic graphical database model that provides efficiency, high availability,
handling huge number of nodes (32 billion), edges (32 billion), and up to 64 billion properties.
As mentioned earlier that will allows all stakeholders that may be involved or interested in
clinical trials data to utilize it for better data management and faster processing time.
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5.2 Limitation and Future Work
The graph database provides a strong but novel data modeling technique even though it
does not in itself provide adequate reasoning for replacing a long-standing, well-understood data
platform; there must also be an immediate and very important practical benefit. The research
established that Neo4j is still an immature tool, hence it is growing progressively to be able to
offer capabilities to serve big enterprise projects and systems.
The current work is still in the process of implementing the concept of GDA for clinical
trials. One of the aspects that will be considered is to extend the architecture into separate server
not only a server embedded within the Java environment. The current architecture though
represent the first step towards a comprehensive architectural model that can imitate for example
SOA. There are many options to extend the GDA concept:
First option is the integration between Neo4j server with Neo4j and .NET Development
Environment that includes a Neo4jClient API and developing a .NET and Neo4j web
application. The second option is pairing Python programming language with Neo4j in a
development environment that includes: Integrated development environment (IDE) like Eclipse,
alongside Python language driver plugin for Neo4j. The third option is using Java with Neo4j.
The Java integrates Neo4j server instance with the Neo4j JDBC driver, also known as Neo4j
JDBC or simply NJDBC.
Finally measuring the performance of the GDA for clinical trials (CT) frequently is
crucial to determine its excellence and productivity due to the continuous growth of clinical data.
The amount of data sets of the new clinical trials, studies, and investigation may affect the
performance of GDA.
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